Instil Bio

TIL

Biotech

Health Care

Pharma

Country

US

Industry

Health Care

Market Cap

Micro Cap

Num. Employees

192

IPO Date

Mar 19, 2021

Create Alert

TIL

Country

US

Industry

Health Care

Biotech

Health Care

+1

Create Alert

Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 192 full-time employees. The company went IPO on 2021-03-19. The firm is focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL), therapies for the treatment of patients with cancer. The company is developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The firm's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.